Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CDOP Combined With Intrathecal Methotrexate for High-Risk DLBCL
NCT05257018Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Started Feb 2022; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05257018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257018.